Results 211 to 220 of about 99,139 (308)

Beta Thalassemia and Chronic Myeloid Leukemia: Dual Diagnosis Under the Microscope

open access: yes
International Journal of Laboratory Hematology, EarlyView.
Paige Muir   +3 more
wiley   +1 more source

Real‐World Outcomes of Mycosis Fungoides and Site‐Specific Nodal Involvement: A Registry‐Based Study of 25 467 Patients

open access: yesAmerican Journal of Hematology, Volume 101, Issue 7, Page 1618-1627, July 2026.
ABSTRACT Mycosis fungoides (MF) is a rare extranodal T‐cell lymphoma with primary cutaneous involvement. While it is the most common primary skin lymphoma, large‐scale real‐world data defining survival benchmarks and the prognostic significance of specific nodal sites remain limited.
Charalampos Filippatos   +4 more
wiley   +1 more source

Olfactory Bulb Volume and Function Recovery in Eosinophilic Chronic Rhinosinusitis

open access: yesThe Laryngoscope, Volume 136, Issue 7, Page 2900-2912, July 2026.
This study investigated perioperative changes in olfactory bulb volume (OBV) in patients with eosinophilic chronic rhinosinusitis using high‐resolution 3T MRI. Postoperative increases in OBV were associated with improvements in olfactory identification, suggesting a potential link between olfactory bulb structural plasticity and functional recovery ...
Keisuke Yamamoto   +8 more
wiley   +1 more source

Toxocariasis in immigrants and travelers with unexplained eosinophilia. [PDF]

open access: yesParasit Vectors
Niño-Puerto L   +7 more
europepmc   +1 more source

Liver Injury From Medications Used for Treating Inflammatory Bowel Disease: The Drug‐Induced Liver Injury Network Experience

open access: yesLiver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background We aimed to investigate and characterise DILI due to approved therapies for inflammatory bowel disease (IBD). Methods Using the Drug‐Induced Liver Injury Network (DILIN) prospective study, we evaluated definite, highly likely, or probable DILI attributed to IBD therapies, including use for non‐IBD indications (but excluding ...
Harish Gopalakrishna   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy